3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
16
Phase 3
7
Phase 1
3
Phase 2/3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
16
Colorectal Neoplasms
8
Stomach Neoplasms
6
Carcinoma, Hepatocellular
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Biliary Tract Neoplasms
4
Rectal Neoplasms
3
Neoplasms
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Esophageal Squamous Cell Carcinoma
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Resected Liver Metastases From Colorectal Cancer
1
Recurrence
1
Quality of Life
1
Oesophagogastric Cancer
1
Malignant Tumor of Pancreas Metastatic to Liver
1
Inflammatory Breast Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-positive Breast Cancer
1
Gastroesophageal Junction Adenocarcinoma
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Breast Diseases
1
Bile Duct Neoplasms
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
Gemcitabine
5
Cisplatin
5
Oxaliplatin
2
pertuzumab
1
durvalumab
1
Trastuzumab
1
Standard of Care
1
Radiotherapy, Intensity-Modulated
1
Platinum
1
Paclitaxel
1
Magnetic Resonance Spectroscopy
1
Lymph Node Excision
1
Laparoscopy
1
Geriatric Assessment
1
Everolimus
1
Drug Therapy
1
Chemoradiotherapy
1
Capecitabine
1
ARRY-334543
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Gallbladder Neoplasms
×
Capecitabine
×
Clear all
NCT03093870
2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3
Completed
151 enrolled
18 charts